Morning Market Gainers

Loading...
Loading...
Giga-tronics, Incorporated GIGA
shares jumped 160.36 percent to $2.89 following the announcement of a software licensing agreement with
Lockheed Martin CorporationLMT
.
Spherix IncSPEX
gained 25.43 percent to $0.439 as the company said it no longer has a $5 million payment due on Series I stock.
TerraForm Power IncTERP
shares gained 19.57 percent to $8.25. Terraform Global is pulling out of deal to acquire shares of Renovia Energia, according to Reuters. David Tepper's Appaloosa issued a letter to TerraForm Power Directors. Analysts at Oppenheimer upgraded TerraForm Power from Perform to Outperform.
Infoblox Inc BLOX
shares rose 19.55 percent to $17.98 after the company reported better-than-expected results for its fiscal first quarter and issued a strong outlook. The company's board also announced a $100 million share buyback program.
HF Financial Corp. HFFC
shares climbed 18.18 percent to $19.18 after
Great Western Bancorp Inc
GWB
announced plans to acquire HF Financial Corp in a transaction valued at $19.70 per share.
XOMA CorpXOMA
Loading...
Loading...
shares rose 13.91 percent to $1.51 after the company reported a license agreement with Novo Nordisk for XMetA program in diabetes.
Abengoa SA (ADR) ABGB
shares surged 14.08 percent to $2.35 after jumping 19.08 percent on Monday.
Rayonier Advanced Materials IncRYAM
rose 11.86 percent to $12.54 after the company reported a new contract with Eastman Chemical through 2019
Mattress Firm Holding Corp MFRM
shares gained 9 percent to $53.80. Mattress Firm agreed to acquire HMK Mattress Holdings LLC, the holding company of Sleepy's and related entities, for $780 million. The company reported preliminary Q3 adjusted earnings of $0.80 to $0.82 per share, and sales growth of 50.7 percent.
Arena Pharmaceuticals, Inc. ARNA
shares gained 8.79 percent to $2.60 after surging 11.16 percent on Monday. Eisai and Arena Pharmaceuticals reported the completion of enrollment in BELVIQ® (lorcaserin HCI) CAMELLIA-TIMI 61 study.
Synthetic Biologics Inc SYN
rose 3.15 percent to $2.95 after announcing positive topline results from first Phase 2A clinical trial of SYN-004 for the prevention of C. difficile infection.
Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
Posted In: NewsIntraday UpdateMarketsMoversAerospace & DefenseIndustrialsMarket GainersTop Gainers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...